This site is intended for healthcare professionals.
izervay-logo

IT’S TIME TO SEE GEOGRAPHIC
ATROPHY DIFFERENTLY

Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that causes irreversible vision loss.1

GA Has a Devastating Impact on Patients’ Lives2

need assistance with daily living3

need assistance with daily living3

with bilateral GA lose their ability to drive within 1.6 years from diagnosis1*

with bilateral GA lose their ability to drive within 1.6 years from diagnosis1*

experience a 10-letter loss
in BCVA in 2 years
from diagnosis4†

experience a 10-letter loss
in BCVA in 2 years
from diagnosis4†

GA can progress from the noncentral area to the foveal center point in just 2.5 years from diagnosis and currently affects ∼5 million people worldwide.1,5

Imaging: Diagnosis and Progression

Imaging: Diagnosis and Progression

Imaging plays a critical role in both the early diagnosis of GA and in the monitoring of disease progression.5

The Role of the Complement System

The Role of the Complement System

Dysregulation of the complement system has been strongly associated with the progression and pathogenesis of GA.6,7

*Findings from a UK retrospective cohort analysis with patients with visual acuity (VA) follow-up. The patients were eligible to drive at baseline according to the UK driving standard (VA measure >70 letters or Snellen 6/12 [US Snellen 20/40] in the better-seeing eye) but lost their vision progressively making them ineligible to drive; 1.6 years represents the median (0.7-2.7 years).8

†Analysis of the Chroma, Spectri, and Proxima A trials, including 2006 patients with GA.4

BCVA=best corrected visual acuity.

References:

  1. Bakri SJ, Bektas M, Sharp D, et al. Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm. 2023;29(5-aSuppl):S2-S11.

  2. Singh RP, Patel SS, Nielsen JS, Schmier J, Rajput Y. Patient-, caregiver-, and eye care professional-reported burden of geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmol Clin Trials. 2019;2(1):1-6.

  3. Patel PJ, Ziemssen F, Ng E, et al. Burden of illness in geographic atrophy: a study of vision-related quality of life and health care resource use. Clin Ophthalmol. 2020;14:15-28.

  4. Anegondi N, Steffen V, Sadda SR, et al. Visual loss in geographic atrophy: learnings from the lampalizumab trials. Ophthalmology. 2025;132(4):420-430.

  5. Sadda SR, Chakravarthy U, Birch DG, Staurenghi G, Henry EC, Brittain C. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. Retina. 2016;36(10):1806-1822.

  6. Boyer DS, Schmidt-Erfuth U, van Lookeren Campagne M, Henry EC, Brittain C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37(5):819-835.

  7. Xu H, Chen M. Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol. 2016;787:94-104.

  8. Chakravarthy U, Bailey CC, Johnston RL, et al. Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125(6):842-849.